Hepaxane

Active Ingredient:: Enoxaparin Sodium
Origin:: EU

Hepaxane (Enoxaparin Sodium)

Q: What is the active ingredient in Hepaxane?

Hepaxane contains enoxaparin sodium, which is a low‑molecular‑weight heparin used as an antithrombotic agent.

Q: For which conditions is Hepaxane prescribed in the European Union?

Hepaxane is prescribed for prevention and treatment of deep vein thrombosis, prevention and treatment of pulmonary embolism, anticoagulation during hemodialysis, and other clinical situations with elevated clotting risk.

Q: How is Hepaxane administered?

The medication is given by injection, either subcutaneously, intravenously, or through the hemodialysis circuit, depending on the clinical indication.

Q: Can Hepaxane be used in patients with kidney disease?

Patients with severe renal impairment (creatinine clearance below 30 mL/min) may require dose adjustment, and renal function should be monitored while on Hepaxane.

Q: What are the most common side effects of Hepaxane?

Common side effects include injection‑site bruising or pain, mild gastrointestinal upset, transient liver‑enzyme elevations, and minor bleeding such as from gums or nose.

Q: What serious adverse reactions should be reported while taking Hepaxane?

Serious reactions include significant bleeding (including internal or intracranial hemorrhage) and thrombocytopenia, particularly heparin‑induced thrombocytopenia (HIT).

Q: Should Hepaxane be avoided with other blood thinners?

Concurrent use of other injectable anticoagulants (e.g., unfractionated heparin, fondaparinux) should be avoided unless specifically monitored, due to increased bleeding risk.

Q: Is it safe to take aspirin or NSAIDs while on Hepaxane?

Aspirin and NSAIDs can increase minor bleeding and should be used with caution; clinicians often assess the overall bleeding risk before combining them.

Q: What monitoring is recommended for patients on Hepaxane?

Routine monitoring may include platelet counts to detect HIT, anti‑Xa activity in certain high‑risk patients, and assessment of renal function for dose adjustments.

Q: Is Hepaxane approved for use during pregnancy?

Safety data for Hepaxane in pregnancy are limited; the medication should only be used if the potential benefit justifies the potential risk to the fetus.

Hepaxane is a prescription medication whose active ingredient is enoxaparin sodium, a low‑molecular‑weight heparin. It is supplied in an injectable form for subcutaneous, intravenous, or hemodialysis administration, although the exact strength and dosage form are not specified in the available product information. Hepaxane is marketed in the European Union and is classified as an antithrombotic agent used to reduce the risk of clot formation in clinical practice.

Manufacturer / TM Owner

Chemi S.P.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Hepaxane is indicated for several antithrombotic purposes where prevention or treatment of venous thromboembolism is required in hospitalized or ambulatory patients.

Prevention of deep vein thrombosis (DVT) in patients undergoing surgery or immobilization.
Treatment of established DVT to reduce clot propagation and recurrence.
Prevention and treatment of pulmonary embolism (PE) in at‑risk individuals.
Anticoagulation during hemodialysis to maintain circuit patency.
Prophylaxis of clot formation in other clinical situations where thrombotic risk is elevated.

Side Effects

Like other low‑molecular‑weight heparins, Hepaxane may cause adverse reactions, most of which are mild and transient, while rare events can be serious.

Common

Injection site bruising, pain, or erythema.
Minor gastrointestinal upset such as nausea or dyspepsia.
Transient elevation of liver enzymes.
Mild bleeding from gums, nose, or minor cuts.

Serious

Significant hemorrhage, including internal or intracranial bleeding.
Thrombocytopenia, especially heparin‑induced thrombocytopenia (HIT).

Precautions & Warnings

Before initiating Hepaxane, clinicians should evaluate patient‑specific factors and monitor for conditions that could increase bleeding risk or affect drug safety throughout therapy.

History of active bleeding, recent surgery, or trauma.
Severe renal impairment (creatinine clearance <30 mL/min) requiring dose adjustment.
Concomitant use of other anticoagulants, antiplatelet agents, or thrombolytics.
Known hypersensitivity to enoxaparin, heparin, or any excipients.
Pregnancy and lactation status should be assessed, as safety data are limited.
Regular monitoring of platelet counts and anti‑Xa levels in high‑risk patients.

Avoid Interactions

Hepaxane can interact with several medications, potentially altering anticoagulant effect or increasing bleeding risk; awareness of these interactions guides safe prescribing in clinical practice.

Avoid

Concurrent use of other injectable anticoagulants (e.g., unfractionated heparin, fondaparinux) without specific monitoring.
Strong antiplatelet drugs such as clopidogrel or ticagrelor when high bleeding risk is present.

Use with caution

Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin, which may increase minor bleeding.
Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents.
Certain antibiotics (e.g., vancomycin) that can potentiate anticoagulant effect.
High‑dose corticosteroids.

Frequently Asked Questions

Hepaxane contains enoxaparin sodium, which is a low‑molecular‑weight heparin used as an antithrombotic agent.

Hepaxane is prescribed for prevention and treatment of deep vein thrombosis, prevention and treatment of pulmonary embolism, anticoagulation during hemodialysis, and other clinical situations with elevated clotting risk.

The medication is given by injection, either subcutaneously, intravenously, or through the hemodialysis circuit, depending on the clinical indication.

Patients with severe renal impairment (creatinine clearance below 30 mL/min) may require dose adjustment, and renal function should be monitored while on Hepaxane.

Common side effects include injection‑site bruising or pain, mild gastrointestinal upset, transient liver‑enzyme elevations, and minor bleeding such as from gums or nose.

Serious reactions include significant bleeding (including internal or intracranial hemorrhage) and thrombocytopenia, particularly heparin‑induced thrombocytopenia (HIT).

Concurrent use of other injectable anticoagulants (e.g., unfractionated heparin, fondaparinux) should be avoided unless specifically monitored, due to increased bleeding risk.

Aspirin and NSAIDs can increase minor bleeding and should be used with caution; clinicians often assess the overall bleeding risk before combining them.

Routine monitoring may include platelet counts to detect HIT, anti‑Xa activity in certain high‑risk patients, and assessment of renal function for dose adjustments.

Safety data for Hepaxane in pregnancy are limited; the medication should only be used if the potential benefit justifies the potential risk to the fetus.

Selective serotonin reuptake inhibitors can increase bleeding risk and should be used with caution when a patient is receiving Hepaxane.

Because Hepaxane is administered by injection on a scheduled basis, patients should contact their healthcare provider for guidance rather than self‑adjusting the dose.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 18 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.